The online version of this article (doi:10.1186/1471-230X-14-28) contains supplementary material, which is available to authorized users.
Edith Vécsei, Stephanie Steinwendner contributed equally to this work.
The authors disclose the following: Drs. Edith Vécsei, Stephanie Steinwendner, Hubert Kogler, Albina Innerhofer, Karin Hammer, Oskar A. Haas, Gabriele Amann, Andreas Chott, Harald Vogelsang, Regine Schoenlechner, and Wolfgang Huf have no financial interests to disclose. Dr. Andreas Vécsei has served as a consultant and scientific advisor for Dr. Schär GmbH/Srl, Burgstall, BZ, Italy.
The study was partially supported by Dr. Schär GmbH/Srl, Burgstall, BZ, Italy, and the St. Anna Fund, Vienna, Austria. Antibody kits were supplied free of charge by Inova Diagnostics, Inc., Werfen Group. The study sponsors were not involved in the study design, in the collection, analysis, interpretation of data and in writing of the report.
EV, SS, HK and AV jointly wrote the first draft of the manuscript. Furthermore, EV developed the study design, the concept and the statistical analysis plan, participated in data collection, interpreted the data and did the statistical analysis and revised the paper; SS developed the study design, the concept and the statistical analysis plan, participated in data collection and entry into the data base, analyzed and interpreted the data; HK cleaned and interpreted the data and participated in statistical analysis and revised the paper and the tables; AI was responsible for the data collection, entry in the database and clinical care of the study patients, critically revised the manuscript for important intellectual content; KH was performing the endoscopies, participated in data collection, was responsible for the clinical care of the study patients, revised the draft paper; OAH was responsible for the serological tests, revised the draft paper; GA and AC reviewed the pathological slides, participated in data collection and revised the draft paper; HV was responsible for the results of the intestinal permeability test and critically revised the manuscript for important intellectual content; RS participated in data collection and revised the paper; WH did the statistical analysis, drafted the figures and critically revised the manuscript for important intellectual content; AV developed the study design, the concept and the statistical analysis plan, obtained the funding, monitored data collection, interpreted the data and did the statistical analysis, drafted and revised the paper and supervised the study. All authors read and approved the final manuscript.
In diagnosing celiac disease (CD), serological tests are highly valuable. However, their role in following up children with CD after prescription of a gluten-free diet is unclear. This study aimed to compare the performance of antibody tests in predicting small-intestinal mucosal status in diagnosis vs. follow-up of pediatric CD.
We conducted a prospective cohort study at a tertiary-care center. 148 children underwent esophohagogastroduodenoscopy with biopsies either for symptoms ± positive CD antibodies (group A; n = 95) or following up CD diagnosed ≥ 1 year before study enrollment (group B; n = 53). Using biopsy (Marsh ≥ 2) as the criterion standard, areas under ROC curves (AUCs) and likelihood-ratios were calculated to estimate the performance of antibody tests against tissue transglutaminase (TG2), deamidated gliadin peptide (DGP) and endomysium (EMA).
AUCs were higher when tests were used for CD diagnosis vs. follow-up: 1 vs. 0.86 (P = 0.100) for TG2-IgA, 0.85 vs. 0.74 (P = 0.421) for TG2-IgG, 0.97 vs. 0.61 (P = 0.004) for DPG-IgA, and 0.99 vs. 0.88 (P = 0.053) for DPG-IgG, respectively. Empirical power was 85% for the DPG-IgA comparison, and on average 33% (range 13–43) for the non-significant comparisons. Among group B children, 88.7% showed mucosal healing (median 2.2 years after primary diagnosis). Only the negative likelihood-ratio of EMA was low enough (0.097) to effectively rule out persistent mucosal injury. However, out of 12 EMA-positive children with mucosal healing, 9 subsequently turned EMA-negative.
Among the CD antibodies examined, negative EMA most reliably predict mucosal healing. In general, however, antibody tests, especially DPG-IgA, are of limited value in predicting the mucosal status in the early years post-diagnosis but may be sufficient after a longer period of time.
Kaukinen K, Peraaho M, Lindfors K, Partanen J, Woolley N, Pikkarainen P, Karvonen AL, Laasanen T, Sievanen H, Maki M, et al: Persistent small bowel mucosal villous atrophy without symptoms in coeliac disease. Aliment Pharmacol Ther. 2007, 25 (10): 1237-1245. 10.1111/j.1365-2036.2007.03311.x. CrossRefPubMed
Lebwohl B, Granath F, Ekbom A, Smedby KE, Murray JA, Neugut AI, Green PH, Ludvigsson JF: Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study. Ann Intern Med. 2013, 159 (3): 169-175. 10.7326/0003-4819-159-3-201308060-00006. CrossRefPubMedPubMedCentral
Husby S, Koletzko S, Korponay-Szabo IR, Mearin ML, Phillips A, Shamir R, Troncone R, Giersiepen K, Branski D, Catassi C, et al: European society for pediatric gastroenterology, hepatology, and nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012, 54 (1): 136-160. 10.1097/MPG.0b013e31821a23d0. CrossRefPubMed
Hill ID, Dirks MH, Liptak GS, Colletti RB, Fasano A, Guandalini S, Hoffenberg EJ, Horvath K, Murray JA, Pivor M, et al: Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2005, 40 (1): 1-19. 10.1097/00005176-200501000-00001. CrossRefPubMed
Hopper AD, Hadjivassiliou M, Hurlstone DP, Lobo AJ, McAlindon ME, Egner W, Wild G, Sanders DS: What is the role of serologic testing in celiac disease? A prospective, biopsy-confirmed study with economic analysis. Clin Gastroenterol Hepatol. 2008, 6 (3): 314-320. 10.1016/j.cgh.2007.12.008. CrossRefPubMed
Jaeschke R, Guyatt GH, Sackett DL: Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA. 1994, 271 (9): 703-707. 10.1001/jama.1994.03510330081039. CrossRefPubMed
R Core Team: R: A Language and Environment for Statistical Computing. 2013, Vienna, Austria: R Foundation for Statistical Computing, http://www.R-project.org/,
Kurppa K, Rasanen T, Collin P, Iltanen S, Huhtala H, Ashorn M, Saavalainen P, Haimila K, Partanen J, Maki M, et al: Endomysial antibodies predict celiac disease irrespective of the titers or clinical presentation. World J Gastroenterol. 2012, 18 (20): 2511-2516. 10.3748/wjg.v18.i20.2511. CrossRefPubMedPubMedCentral
- Follow-up of pediatric celiac disease: value of antibodies in predicting mucosal healing, a prospective cohort study
Oskar A Haas
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II